Ken Griffin 89bio, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$7.36 - $9.66 $167,808 - $220,248	-22,800 Reduced 22.87%	76,900 $569,000
Q2 2024 Aug 14, 2024	BUY	$7.31 - $10.9 $276,318 - $412,020	37,800 Added 61.07%	99,700 $798,000
Q1 2024 May 15, 2024	BUY	$8.13 - $13.77 $26,016 - $44,064	3,200 Added 5.45%	61,900 $720,000
Q4 2023 Feb 14, 2024	SELL	$6.66 - $16.03 $32,634 - $78,547	-4,900 Reduced 7.7%	58,700 $655,000
Q3 2023 Nov 14, 2023	SELL	$15.06 - $19.41 $39,156 - $50,466	-2,600 Reduced 3.93%	63,600 $981,000
Q2 2023 Aug 14, 2023	SELL	$14.15 - $22.03 $1.8 Million - $2.8 Million	-127,000 Reduced 65.73%	66,200 $1.25 Million
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $1.93 Million - $3.13 Million	184,500 Added 2120.69%	193,200 $2.94 Million
Q4 2022 Feb 14, 2023	SELL	$5.52 - $12.73 $99,911 - $230,413	-18,100 Reduced 67.54%	8,700 $110,000
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $80,936 - $187,600	26,800 New	26,800 $155,000

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $441M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.